Advancements in the development of antivirals against SARS-Coronavirus
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused an outbreak in 2002-2003, spreading to 29 countries with a mortality rate of about 10%. Strict quarantine and infection control methods quickly stopped the spread of the disease. Later research showed that SARS-CoV came from animals (zo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1520811/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590852984143872 |
|---|---|
| author | Mrityunjay Kumar Mirza Sarwar Baig Kanchan Bhardwaj Kanchan Bhardwaj |
| author_facet | Mrityunjay Kumar Mirza Sarwar Baig Kanchan Bhardwaj Kanchan Bhardwaj |
| author_sort | Mrityunjay Kumar |
| collection | DOAJ |
| description | Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused an outbreak in 2002-2003, spreading to 29 countries with a mortality rate of about 10%. Strict quarantine and infection control methods quickly stopped the spread of the disease. Later research showed that SARS-CoV came from animals (zoonosis) and stressed the possibility of a similar spread from host to human, which was clearly shown by the COVID-19 outbreak. The COVID-19 pandemic, instigated by SARS-CoV-2, has affected 776 million confirmed cases and more than seven million deaths globally as of Sept 15, 2024. The existence of animal reservoirs of coronaviruses continues to pose a risk of re-emergence with improved fitness and virulence. Given the high death rate (up to 70 percent) and the high rate of severe sickness (up to 68.7 percent in long-COVID patients), it is even more critical to identify new therapies as soon as possible. This study combines research on antivirals that target SARS coronaviruses that have been conducted over the course of more than twenty years. It is a beneficial resource that might be useful in directing future studies. |
| format | Article |
| id | doaj-art-e84a04829ecc4fa88d6090d17cc991e0 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-e84a04829ecc4fa88d6090d17cc991e02025-01-23T06:56:23ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-01-011510.3389/fcimb.2025.15208111520811Advancements in the development of antivirals against SARS-CoronavirusMrityunjay Kumar0Mirza Sarwar Baig1Kanchan Bhardwaj2Kanchan Bhardwaj3Department of Biotechnology, School of Engineering and Technology, Manav Rachna International Institute of Research and Studies, Faridabad, IndiaCentre for Virology, School of Interdisciplinary Science and Technology, Jamia Hamdard, New Delhi, IndiaDepartment of Biotechnology, School of Engineering and Technology, Manav Rachna International Institute of Research and Studies, Faridabad, IndiaRegional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, IndiaSevere Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused an outbreak in 2002-2003, spreading to 29 countries with a mortality rate of about 10%. Strict quarantine and infection control methods quickly stopped the spread of the disease. Later research showed that SARS-CoV came from animals (zoonosis) and stressed the possibility of a similar spread from host to human, which was clearly shown by the COVID-19 outbreak. The COVID-19 pandemic, instigated by SARS-CoV-2, has affected 776 million confirmed cases and more than seven million deaths globally as of Sept 15, 2024. The existence of animal reservoirs of coronaviruses continues to pose a risk of re-emergence with improved fitness and virulence. Given the high death rate (up to 70 percent) and the high rate of severe sickness (up to 68.7 percent in long-COVID patients), it is even more critical to identify new therapies as soon as possible. This study combines research on antivirals that target SARS coronaviruses that have been conducted over the course of more than twenty years. It is a beneficial resource that might be useful in directing future studies.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1520811/fullCOVID-19long COVIDSARS coronavirusbetacoronavirusantivirals |
| spellingShingle | Mrityunjay Kumar Mirza Sarwar Baig Kanchan Bhardwaj Kanchan Bhardwaj Advancements in the development of antivirals against SARS-Coronavirus Frontiers in Cellular and Infection Microbiology COVID-19 long COVID SARS coronavirus betacoronavirus antivirals |
| title | Advancements in the development of antivirals against SARS-Coronavirus |
| title_full | Advancements in the development of antivirals against SARS-Coronavirus |
| title_fullStr | Advancements in the development of antivirals against SARS-Coronavirus |
| title_full_unstemmed | Advancements in the development of antivirals against SARS-Coronavirus |
| title_short | Advancements in the development of antivirals against SARS-Coronavirus |
| title_sort | advancements in the development of antivirals against sars coronavirus |
| topic | COVID-19 long COVID SARS coronavirus betacoronavirus antivirals |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1520811/full |
| work_keys_str_mv | AT mrityunjaykumar advancementsinthedevelopmentofantiviralsagainstsarscoronavirus AT mirzasarwarbaig advancementsinthedevelopmentofantiviralsagainstsarscoronavirus AT kanchanbhardwaj advancementsinthedevelopmentofantiviralsagainstsarscoronavirus AT kanchanbhardwaj advancementsinthedevelopmentofantiviralsagainstsarscoronavirus |